COL6A3 and glioblastoma: Interestingly, we observed that COL6A3+ TAFs were primarily localized in areas of GBM microvascular proliferation following neoadjuvant combination therapy, potentially blocking the infiltration of T cells and thereby impairing antitumor immunity.